Progyny (PGNY) Scheduled to Post Earnings on Thursday

Progyny (NASDAQ:PGNY) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of $0.14 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.04. The business had revenue of $269.94 million during the quarter, compared to the consensus estimate of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.03 earnings per share. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Price Performance

Shares of PGNY stock opened at $32.40 on Tuesday. The firm has a fifty day moving average of $34.95 and a two-hundred day moving average of $35.62. The firm has a market cap of $3.11 billion, a P/E ratio of 52.26, a P/E/G ratio of 1.31 and a beta of 1.51. Progyny has a 1-year low of $29.44 and a 1-year high of $44.95.

Analysts Set New Price Targets

Several analysts have issued reports on PGNY shares. Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price objective on shares of Progyny in a research note on Wednesday, February 28th. KeyCorp reduced their price objective on Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th. Leerink Partnrs reiterated an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Truist Financial restated a “buy” rating and issued a $46.00 price target on shares of Progyny in a research report on Wednesday, April 17th. Finally, SVB Leerink initiated coverage on shares of Progyny in a report on Monday, February 26th. They issued an “outperform” rating and a $49.00 price target for the company. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, Progyny presently has an average rating of “Buy” and a consensus target price of $48.30.

Insider Buying and Selling at Progyny

In other Progyny news, Chairman David J. Schlanger sold 71,272 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total value of $2,694,081.60. Following the sale, the chairman now owns 86,312 shares in the company, valued at $3,262,593.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, President Michael E. Sturmer sold 4,515 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $144,254.25. Following the completion of the sale, the president now owns 380,038 shares of the company’s stock, valued at $12,142,214.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman David J. Schlanger sold 71,272 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the transaction, the chairman now directly owns 86,312 shares in the company, valued at approximately $3,262,593.60. The disclosure for this sale can be found here. Insiders sold 102,770 shares of company stock valued at $3,853,985 in the last ninety days. Company insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.